MedTrace Logo

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

NCT00165230 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2009-04-28

No results posted yet for this study

Summary

The purpose of this study is to find out what effects, good or bad, that thalidomide and temodar have on patients with neuroendocrine tumors.

Conditions

  • Neuroendocrine Tumor

Interventions

DRUG

Thalidomide

DRUG

Temodar

Sponsors & Collaborators

Principal Investigators

  • Matthew H. Kulke, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Primary Completion
2006-07-31
Completion
2006-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165230 on ClinicalTrials.gov